HC Wainwright Issues Positive Estimate for ALDX Earnings

Aldeyra Therapeutics, Inc (NASDAQ:ALDX) – Equities research analysts at HC Wainwright increased their Q2 2025 EPS estimates for Aldeyra Therapeutics in a report released on Monday, May 19th. HC Wainwright analyst M. Caufield now expects that the biotechnology company will post earnings of ($0.18) per share for the quarter, up from their prior forecast of ($0.26). HC Wainwright has a “Buy” rating and a $10.00 price objective on the stock. The consensus estimate for Aldeyra Therapeutics’ current full-year earnings is ($0.92) per share. HC Wainwright also issued estimates for Aldeyra Therapeutics’ Q3 2025 earnings at ($0.12) EPS, Q4 2025 earnings at ($0.07) EPS, FY2025 earnings at ($0.54) EPS, FY2026 earnings at ($0.26) EPS, FY2027 earnings at $0.26 EPS and FY2028 earnings at $0.64 EPS.

Aldeyra Therapeutics (NASDAQ:ALDX) last issued its quarterly earnings results on Wednesday, May 14th. The biotechnology company reported ($0.17) EPS for the quarter, beating the consensus estimate of ($0.25) by $0.08.

A number of other brokerages have also issued reports on ALDX. StockNews.com raised Aldeyra Therapeutics to a “sell” rating in a research note on Wednesday. BTIG Research reduced their target price on Aldeyra Therapeutics from $11.00 to $9.00 and set a “buy” rating on the stock in a research note on Monday, April 7th.

Aldeyra Therapeutics Stock Down 2.5%

Shares of NASDAQ:ALDX opened at $2.36 on Wednesday. The firm has a market capitalization of $141.35 million, a PE ratio of -2.43 and a beta of 0.92. The business has a 50 day simple moving average of $3.38 and a two-hundred day simple moving average of $4.69. Aldeyra Therapeutics has a 1 year low of $1.14 and a 1 year high of $7.20. The company has a debt-to-equity ratio of 0.18, a current ratio of 6.80 and a quick ratio of 6.80.

Hedge Funds Weigh In On Aldeyra Therapeutics

Several institutional investors have recently made changes to their positions in the company. Hsbc Holdings PLC purchased a new stake in Aldeyra Therapeutics in the fourth quarter worth about $52,000. Balyasny Asset Management L.P. bought a new position in shares of Aldeyra Therapeutics during the fourth quarter valued at approximately $56,000. Capital Advisors Wealth Management LLC bought a new position in shares of Aldeyra Therapeutics during the first quarter valued at approximately $62,000. Wealth Enhancement Advisory Services LLC purchased a new position in Aldeyra Therapeutics during the first quarter valued at approximately $63,000. Finally, Catalyst Funds Management Pty Ltd raised its stake in Aldeyra Therapeutics by 2,083.3% in the fourth quarter. Catalyst Funds Management Pty Ltd now owns 13,100 shares of the biotechnology company’s stock worth $65,000 after buying an additional 12,500 shares in the last quarter. Hedge funds and other institutional investors own 59.71% of the company’s stock.

Insider Buying and Selling at Aldeyra Therapeutics

In other Aldeyra Therapeutics news, major shareholder Perceptive Advisors Llc sold 3,400,000 shares of the company’s stock in a transaction on Thursday, April 3rd. The stock was sold at an average price of $1.42, for a total value of $4,828,000.00. Following the completion of the sale, the insider now directly owns 5,875,851 shares in the company, valued at approximately $8,343,708.42. This represents a 36.65% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 9.60% of the stock is owned by corporate insiders.

About Aldeyra Therapeutics

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.